{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T06:51:30Z","timestamp":1791528690493,"version":"4.3.4"},"reference-count":9,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.ejca.2026.117767","type":"journal-article","created":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T15:28:16Z","timestamp":1790954896000},"page":"117767","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Letter Re: \u201cA stromal\u2013immune computational pathology signature for prognosis and immune checkpoint inhibitor response in localized, locally advanced and metastatic urothelial carcinoma: A multicenter retrospective study\u201d"],"prefix":"10.1016","volume":"248","author":[{"given":"Yan","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingyuan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5704-400X","authenticated-orcid":false,"given":"Ting","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2026.117767_bib1","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2026.116979","article-title":"A stromal-immune computational pathology signature for prognosis and immune checkpoint inhibitor response in localized, locally advanced and metastatic urothelial carcinoma: a multicenter retrospective study","volume":"246","author":"Song","year":"2026","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2026.117767_bib2","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/S0140-6736(86)90837-8","article-title":"Statistical methods for assessing agreement between two methods of clinical measurement","volume":"1","author":"Bland","year":"1986","journal-title":"Lancet"},{"key":"10.1016\/j.ejca.2026.117767_bib3","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1038\/s43018-021-00232-6","article-title":"Mature tertiary lymphoid structures predict immune checkpoint inhibitor efficacy in solid tumors independently of PD-L1 expression","volume":"2","author":"Vanhersecke","year":"2021","journal-title":"Nat Cancer"},{"key":"10.1016\/j.ejca.2026.117767_bib4","doi-asserted-by":"crossref","first-page":"25","DOI":"10.32604\/or.2026.077808","article-title":"Germinal center-like tertiary lymphoid structures mark immune responsiveness and enable checkpoint immunotherapy in bladder cancer","volume":"34","author":"Yin","year":"2026","journal-title":"Oncol Res"},{"key":"10.1016\/j.ejca.2026.117767_bib5","article-title":"The tumor immune landscape and architecture of tertiary lymphoid structures in urothelial cancer","volume":"12","author":"van Dijk","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.ejca.2026.117767_bib6","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2023-078378","article-title":"TRIPOD+AI statement: updated guidance for reporting clinical prediction models that use regression or machine learning methods","volume":"385","author":"Collins","year":"2024","journal-title":"Bmj"},{"key":"10.1016\/j.ejca.2026.117767_bib7","doi-asserted-by":"crossref","first-page":"e248","DOI":"10.1093\/oncolo\/oyad283","article-title":"Presence, subtypes, and prognostic significance of tertiary lymphoid structures in urothelial carcinoma of the bladder","volume":"29","author":"Ma","year":"2024","journal-title":"Oncologist"},{"key":"10.1016\/j.ejca.2026.117767_bib8","doi-asserted-by":"crossref","first-page":"1850","DOI":"10.1200\/JCO.2009.25.4599","article-title":"Prognostic factors in patients with advanced transitional cell carcinoma of the urothelial tract experiencing treatment failure with platinum-containing regimens","volume":"28","author":"Bellmunt","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2026.117767_bib9","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1056\/NEJMoa2312117","article-title":"Enfortumab vedotin and pembrolizumab in untreated advanced urothelial cancer","volume":"390","author":"Powles","year":"2024","journal-title":"N Engl J Med"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804926015492?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804926015492?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T06:39:43Z","timestamp":1791527983000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804926015492"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":9,"alternative-id":["S0959804926015492"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2026.117767","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Letter Re: \u201cA stromal\u2013immune computational pathology signature for prognosis and immune checkpoint inhibitor response in localized, locally advanced and metastatic urothelial carcinoma: A multicenter retrospective study\u201d","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2026.117767","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"117767"}}